The role of medications in successful aging

References

• Depp CA, Jeste DV. Definitions and predictors of successful aging: a comprehensive review of larger quantitative studies. Am J Geriatr Psychiatry. 2006;14(1):6–20.
   PubMed Web of Science ®Google Scholar
• El Khoudary SR, Aggarwal B, Beckie TM, et al. Menopause transition and cardiovascular disease risk: implications for timing of early prevention: a scientific statement from the American Heart Association. Circulation. 2020;142(25):e506–e532.
   PubMed Web of Science ®Google Scholar
• Cooper C, Ferrari S. IOF compendium of osteoporosis, 2nd ed. Nyon: International Osteoporosis Foundation; 2019. p. 14.
   Google Scholar
• Cowie CC, Casagrande SS, Geiss LS, et al. Prevalence and incidence of type 2 diabetes and prediabetes. In: Cowie CC, Casagrande SS, Menke A, Editors. Chapter 3 in Diabetes in America, 3rd ed. Bethesda, MD: National Institutes of Health, NIH Pub No. 17-1468; 2018.
   Google Scholar
• Bromberger JT, Matthews KA, Schott LL, et al. Depressive symptoms during the menopausal transition: the Study of Women's Health Across the Nation (SWAN). J Affect Disord. 2007;103(1–3):267–272.
   PubMed Web of Science ®Google Scholar
• [cited 2021 Apr 03]. Available from: https://www.who.int/data/gho/data/themes/mortality-and-global-health-estimates/ghe-leading-causes-of-death.
   Google Scholar
• [cited 2021 Apr 03]. Available from: https://www.who.int/data/gho/data/themes/mortality-and-global-health-estimates/global-health-estimates-leading-causes-of-dalys.
   Google Scholar
• Manson JE, Hsia J, Johnson KC, et al. Estrogen plus progestin and the risk of coronary heart disease. N Engl J Med. 2003;349(6):523–534.
   PubMed Web of Science ®Google Scholar
• Wassertheil-Smoller S, Hendrix SL, Limacher M, et al. Effect of estrogen plus progestin on stroke in postmenopausal women: the Women’s Health Initiative: a randomized trial. JAMA. 2003;289(20):2673–2684.
   PubMed Web of Science ®Google Scholar
• Anderson GL, Limacher M, Assaf AR, et al. Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: the Women’s Health Initiative randomized controlled trial. JAMA. 2004;291(14):1701–1712.
   PubMed Web of Science ®Google Scholar
• Boardman HM, Hartley L, Eisinga A, et al. Hormone therapy for preventing cardiovascular disease in post-menopausal women. Cochrane Database Syst Rev. 2015;(3):CD002229.
   Google Scholar
• Vinogradova Y, Coupland C, Hippisley-Cox J. Use of hormone replacement therapy and risk of venous thromboembolism: nested case-control studies using the QResearch and CPRD data-bases. BMJ. 2019;364:k4810.
   PubMed Web of Science ®Google Scholar
• Simon JA, Laliberté F, Duh MS, et al. Venous thromboembolism and cardiovascular disease complications in menopausal women using transdermal versus oral estrogen therapy. Menopause. 2016;23(6):600–610.
   PubMed Web of Science ®Google Scholar
• Salpeter SR, Walsh JM, Greyber E, et al. Brief report: Coronary heart disease events associated with hormone therapy in younger and older women. A meta-analysis [published correction appears. J Gen Intern Med. 2006;21(4):363–366.
   PubMed Web of Science ®Google Scholar
• Petretta M, Costanzo P, Perrone-Filardi P, et al. Impact of gender in primary prevention of coronary heart disease with statin therapy: a meta-analysis. Int J Cardiol. 2010;138(1):25–31.
   PubMed Web of Science ®Google Scholar
• Brugts JJ, Yetgin T, Hoeks SE, et al. The benefits of statins in people without established cardiovascular disease but with cardiovascular risk factors: meta-analysis of randomised controlled trials. BMJ. 2009;338:b2376.
   PubMed Web of Science ®Google Scholar
• Anderson GL, Chlebowski RT, Rossouw JE, et al. Prior hormone therapy and breast cancer risk in the Women’s Health Initiative randomized trial of estrogen plus progestin. Maturitas. 2006;55(2):103–115.
   PubMed Web of Science ®Google Scholar
• Hodis HN, Mack WJ. Postmenopausal hormone therapy in clinical perspective. Menopause. 2007;14(5):944–957.
   PubMed Web of Science ®Google Scholar
• Mora S, Glynn RJ, Hsia J, et al. Statins for the primary prevention of cardiovascular events in women with elevated high-sensitivity C-reactive protein or dyslipidemia: results from the Justification for the Use of Statins in Prevention: An Intervention Trial Evaluating Rosuvastatin (JUPITER) and meta-analysis of women from primary prevention trials. Circulation. 2010;121(9):1069–1077.
   PubMed Web of Science ®Google Scholar
• Ganda OP. Statin-induced diabetes: incidence, mechanisms, and implications. F1000Res. 2016;5:1499.
   Google Scholar
• Henriksbo BD, Lau TC, Cavallari JF, et al. Fluvastatin causes NLRP3 inflammasome-mediated adipose insulin resistance. Diabetes. 2014;63(11):3742–3747.
   PubMed Web of Science ®Google Scholar
• Kautzky-Willer A, Harreiter J, Pacini G. Sex and gender differences in risk, pathophysiology and complications of type 2 diabetes mellitus. Endocr Rev. 2016;37(3):278–316.
   PubMed Web of Science ®Google Scholar
• Hamarsheh S, Zeiser R. NLRP3 Inflammasome activation in cancer: a double-edged sword. Front Immunol. 2020;11:1444.
   PubMed Web of Science ®Google Scholar
• Herring MJ, Avdalovic MV, Lasley B, et al. Elderly female rhesus macaques preserve lung alveoli with estrogen/progesterone therapy. Anat Rec. 2016;299(7):973–978.
   Google Scholar
• Carlson CL, Cushman M, Enright PL, et al. Newman AB; Cardiovascular Health Study Research Group. Hormone replacement therapy is associated with higher FEV1 in elderly women. Am J Respir Crit Care Med. 2001;163(2):423–428.
   PubMed Web of Science ®Google Scholar
• Salpeter SR, Walsh JM, Ormiston TM, et al. Meta-analysis: effect of hormone-replacement therapy on components of the metabolic syndrome in postmenopausal women. Diabetes Obes Metab. 2006;8(5):538–554.
   PubMed Web of Science ®Google Scholar
• Manson JE, Chlebowski RT, Stefanick ML, et al. Menopausal hormone therapy and health outcomes during the intervention and extended poststopping phases of the Women’s Health Initiative randomized trials. JAMA. 2013;310(13):1353–1368.
   PubMed Web of Science ®Google Scholar
• Kanaya AM, Herrington D, Vittinghoff E, et al. Glycemic effects of postmenopausal hormone therapy: the Heart and Estrogen/progestin Replacement Study. A randomized, double-blind, placebo-controlled trial. Ann Intern Med. 2003;138(1):1–9.
   PubMed Web of Science ®Google Scholar
• Shumaker SA, Legault C, Kuller L, et al. Conjugated equine estrogens and incidence of probable dementia and mild cognitive impairment in postmenopausal women: Women’s Health Initiative Memory Study. JAMA. 2004;291(24):2947–2958.
   PubMed Web of Science ®Google Scholar
• Manson JE, Aragaki AK, Rossouw JE, et al. Menopausal hormone therapy and long-term all-cause and cause-specific mortality: The Women's Health Initiative Randomized Trials. JAMA. 2017;318(10):927–938.
   PubMed Web of Science ®Google Scholar
• Kilicdag EB, Yavuz H, Bagis T, et al. Effects of estrogen therapy on hearing in postmenopausal women. Am J Obstet Gynecol. 2004;190(1):77–82.
   PubMed Web of Science ®Google Scholar
• Suh MJ, Oh SK, Lee SB, et al. Effects of endogenous and exogenous oestrogen exposure on hearing level in postmenopausal women: a cross-sectional study. Clin Otolaryngol. 2021;46(3):508–514.
   Web of Science ®Google Scholar
• Chlebowski RT, Anderson GL, Aragaki AK, et al. Association of menopausal hormone therapy with breast cancer incidence and mortality during long-term follow-up of the Women’s Health Initiative Randomized Clinical Trials. JAMA. 2020;324(4):369–380.
   PubMed Web of Science ®Google Scholar
• Chlebowski RT, Hendrix SL, Langer RD, et al. WHI Investigators. Influence of estrogen plus progestin on breast cancer and mammography in healthy postmenopausal women: the Women’s Health Initiative Randomized Trial. JAMA. 2003;289(24):3243–3253.
   PubMed Web of Science ®Google Scholar
• Schierbeck LL, Rejnmark L, Tofteng CL, et al. Effect of hormone replacement therapy on cardiovascular events in recently postmenopausal women: randomised trial. BMJ. 2012;345:e6409.
   PubMed Web of Science ®Google Scholar
• Collaborative Group on Hormonal Factors in Breast Cancer. Type and timing of menopausal hormone therapy and breast cancer risk: individual participant meta-analysis of the worldwide epidemiological evidence. Lancet. 2019;394:1159–1168.
   PubMed Web of Science ®Google Scholar
• Fournier A, Berrino F, Riboli E, et al. Breast cancer risk in relation to different types of hormone replacement therapy in the E3N-EPIC cohort. Int J Cancer. 2005;114(3):448–445.
   PubMed Web of Science ®Google Scholar
• Fournier A, Berrino F, Clavel-Chapelon F. Unequal risks for breast cancer associated with different hormone replacement therapies: Results from the E3N cohort study. Breast Cancer Res Treat. 2008;107(1):103–111.
   PubMed Web of Science ®Google Scholar
• Cauley J, Robbins J, Chen Z, et al. Effects of estrogen plus progestin on risk of fracture and bone mineral density: the Women’s Health Initiative randomized trial. JAMA. 2003;290(13):1729–1738.
   PubMed Web of Science ®Google Scholar
• Jackson RD, Wactawski-Wende J, LaCroix AZ, et al. Effects of conjugated equine estrogen on risk of fractures and BMD in postmenopausal women with hysterectomy: results from the women’s health initiative randomized trial. J Bone Miner Res. 2006;21(6):817–828.
   PubMed Web of Science ®Google Scholar
• Rossouw JE, Anderson GL, Prentice RL, et al. Writing Group for the Women’s Health Initiative Investigators. Risks and benefits of estrogen plus progestin for healthy postmenopausal women. JAMA. 2002;288:321–333.
   PubMed Web of Science ®Google Scholar
• Cummings SR, Black DM, Thompson DE, et al. Effect of alendronate on risk of fracture in women with low bone density but without vertebral fractures: results from the Fracture Intervention Trial. JAMA. 1998;280(24):2077–2082.
   PubMed Web of Science ®Google Scholar
• Wang Z, Ward MM, Chan L, et al. Adherence to oral bisphosphonates and the risk of subtrochanteric and femoral shaft fractures among female medicare beneficiaries. Osteoporos Int. 2014;25(8):2109–2116.
   PubMed Web of Science ®Google Scholar
• Black DM, Abrahamsen B, Bouxsein ML, et al. Atypical femur fractures: review of epidemiology, relationship to bisphosphonates, prevention, and clinical management. Endocr Rev. 2019;40(2):333–368.
   PubMed Web of Science ®Google Scholar
• Black DM, Delmas PD, Eastell R, et al. Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis. N Engl J Med. 2007;356(18):1809–1822.
   PubMed Web of Science ®Google Scholar
• Kim SY, Kim MJ, Cadarette SM, et al. Bisphosphonates and risk of atrial fibrillation: a meta-analysis. Arthritis Res Ther. 2010;12(1):R30.
   PubMed Web of Science ®Google Scholar
• Kim DH, Rogers JR, Fulchino LA, et al. Bisphosphonates and risk of cardiovascular events: a meta-analysis. PLoS One. 2015;10(4):e0122646.
   PubMed Web of Science ®Google Scholar
• Ruggiero SL, Dodson TB, Fantasia J, et al. American Association of Oral and Maxillofacial Surgeons position paper on medication-related osteonecrosis of the jaw–2014 update. J Oral Maxillofac Surg. 2014;72(10):1938–1956.
   PubMed Web of Science ®Google Scholar
• Fuggle NR, Cooper C, Harvey NC, et al. Assessment of cardiovascular safety of anti-osteoporosis drugs. Drugs. 2020;80(15):1537–1552.
   PubMed Web of Science ®Google Scholar
• de Oliveira CC, Brizeno LA, de Sousa FB, et al. Osteonecrosis of the jaw induced by receptor activator of nuclear factor-kappa B ligand (Denosumab) – Review. Med Oral Patol Oral Cir Bucal. 2016;21(4):e431–e439.
   PubMed Web of Science ®Google Scholar
• Blackman JA, Coogan PF, Rosenberg L, et al. Estrogen replacement therapy and risk of lung cancer. Pharmacoepidemiol Drug Saf. 2002;11(7):561–567.
   PubMed Web of Science ®Google Scholar
• Maki PM, Kornstein S, Joffe h, et al. guidelines for the Evaluation and Treatment of Perimenopausal Depression: Summary and Recommendations. J Womens Health. 2019;28(2):117–134.
   PubMed Web of Science ®Google Scholar
• Gordon JL, Rubinow DR, Eisenlohr-Moul TA, et al. Efficacy of transdermal estradiol and micronized progesterone in the prevention of depressive symptoms in the menopause transition: a randomized clinical trial. JAMA Psychiatry. 2018;75(2):149–157.
   PubMed Web of Science ®Google Scholar
• Sheu YH, Lanteigne A, Stürmer T, et al. SSRI use and risk of fractures among perimenopausal women without mental disorders. Inj Prev. 2015;21(6):397–403.
   PubMed Web of Science ®Google Scholar
• Khanassov V, Hu J, Reeves D, et al. Selective serotonin reuptake inhibitor and selective serotonin and norepinephrine reuptake inhibitor use and risk of fractures in adults: a systematic review and meta-analysis. Int J Geriatr Psychiatry. 2018;33(12):1688–1708.
   PubMed Web of Science ®Google Scholar
• Nevitt MC, Cummings SR, Lane NE, et al. Association of estrogen replacement therapy with the risk of osteoarthritis of the hip in elderly white women. Study of Osteoporotic Fractures Research Group. Arch Intern Med. 1996;156(18):2073–2080.
   PubMedGoogle Scholar
• Cirillo DJ, Wallace RB, Wu L, et al. Effect of hormone therapy on risk of hip and knee joint replacement in the Women’s Health Initiative. Arthritis Rheum. 2006;54(10):3194–3204.
   PubMed Web of Science ®Google Scholar
• Park JH, Hong JY, Han K, et al. Relationship between hormone replacement therapy and spinal osteoarthritis: a nationwide health survey analysis of the elderly Korean population. BMJ Open. 2017;7(11):e018063.
   PubMed Web of Science ®Google Scholar
• Jung JH, Bang CH, Song GG, et al. Knee osteoarthritis and menopausal hormone therapy in postmenopausal women: a nationwide cross-sectional study. Menopause. 2018;26(6):598–602.
   PubMed Web of Science ®Google Scholar
• Erdem U, Muftuoglu O, Goktolga U, et al. Effect of hormone replacement therapy in women on ocular refractive status and aberrations. J Refract Surg. 2007;23(6):567–572.
   PubMed Web of Science ®Google Scholar
• Park YJ, Kim JM. Klotho and postmenopausal hormone replacement therapy in women with chronic kidney disease. J Menopausal Med. 2018;24(2):75–80.
   PubMedGoogle Scholar
• Salpeter S, Walsh JM, Greyber E, et al. Mortality associated with hormone replacement therapy in younger and older women: a meta-analysis. J Gen Intern Med. 2004;19(7):791–804.
   PubMed Web of Science ®Google Scholar
• Salpeter SR, Buckley NS, Liu H, et al. The cost-effectiveness of hormone therapy in younger and older postmenopausal women. Am J Med. 2009;122(1):42–52.
   PubMed Web of Science ®Google Scholar
• Langer RD, Hodis HN, Lobo RA, et al. Hormone replacement therapy – where are we now? Climacteric. 2021;24(1):3–10.
   PubMed Web of Science ®Google Scholar